Viridian Therapeutics
VRDN
31 hedge funds and large institutions have $57.4M invested in Viridian Therapeutics in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 5 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
94% more funds holding
Funds holding: 16 → 31 (+15)
32% more capital invested
Capital invested by funds: $43.5M → $57.4M (+$13.9M)
0.29% more ownership
Funds ownership: 1.09% → 1.38% (+0.29%)
Top Buyers
| 1 |
BlackRock
New York
|
+$5.8M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$1.34M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.19M |
| 4 |
Goldman Sachs
New York
|
+$645K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$396K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
26
STRS Ohio
Columbus,
Ohio
| $47K | +$41.7K | +247 | New |
|
27
Legal & General Group
London,
United Kingdom
| $24K | +$20.6K | +122 | New |
|
28
UBS Group
Zurich,
Switzerland
| $20K | +$17.7K | +105 | New |
|
29
BNP Paribas Financial Markets
Paris,
France
| $17.1K | +$14.9K | +88 | New |
|
30
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | +$844 | +5 | New |
|
31
Millennium Management
New York
| – | -$811K | -4,347 | Closed |
|
|
DY
32
Dowling & Yahnke
San Diego,
California
| – | -$498K | -2,666 | Closed |
|
33
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$177K | -946 | Closed |
|
|
SCM
34
Segantii Capital Management
Hong Kong
| – | -$77K | -415 | Closed |
|
35
Creative Planning
Overland Park,
Kansas
| – | -$8K | -44 | Closed |
|
36
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$169 | +1 | New |
|
VRDN Hedge Fund Activity: Q2 2017 in Review
31 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2017, worth a combined $57.4M — up 32% from $43.5M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VRDN positions and 5 closed out — a net gain of 15 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, adding an estimated $5.8M. The largest seller was Millennium Management, exiting entirely with an estimated $811K sold.
- 31 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2017, up from 16 in Q1 2017.
- Funds reported $57.4M of Viridian Therapeutics stock for Q2 2017, up 32% quarter-over-quarter.
- 20 funds opened new Viridian Therapeutics positions in Q2 2017 and 5 closed out, a net change of +15 holders.
- The largest Viridian Therapeutics buyer in Q2 2017 was BlackRock, an estimated $5.8M added.
- The largest Viridian Therapeutics seller in Q2 2017 was Millennium Management, an estimated $811K sold.
Based on aggregated 13F filings for Q2 2017.